Profile data is unavailable for this security.
About the company
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
- Revenue in USD (TTM)44.79m
- Net income in USD-401.27m
- Incorporated2007
- Employees486.00
- LocationAgios Pharmaceuticals Inc88 Sidney StreetCAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 649-8600
- Fax+1 (302) 655-5049
- Websitehttps://www.agios.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics Inc | 181.54m | 20.95m | 1.43bn | 147.00 | 78.03 | 4.91 | 48.69 | 7.85 | 0.2506 | 0.2506 | 2.20 | 3.98 | 0.4685 | -- | 65.30 | 1,354,761.00 | 5.41 | -33.14 | 6.24 | -39.19 | -- | -- | 11.54 | -563.84 | -- | -- | 0.00 | -- | -- | -- | 46.29 | -- | 23.56 | -- |
| Trevi Therapeutics Inc | 0.00 | -45.86m | 1.47bn | 26.00 | -- | 7.74 | -- | -- | -0.3713 | -0.3713 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -34.19 | -45.07 | -36.67 | -51.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -64.84 | -- | 31.21 | -- |
| Amylyx Pharmaceuticals Inc | 0.00 | -149.28m | 1.54bn | 123.00 | -- | 4.62 | -- | -- | -1.80 | -1.80 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.67 | -51.56 | -55.94 | -60.70 | -- | -- | -- | -118.26 | -- | -- | 0.00 | -- | -77.06 | 127.75 | -712.42 | -- | -- | -- |
| Biohaven Ltd | 0.00 | -780.11m | 1.54bn | 256.00 | -- | -- | -- | -- | -7.60 | -7.60 | 0.00 | -0.1622 | 0.00 | -- | -- | 0.00 | -169.65 | -- | -238.45 | -- | -- | -- | -- | -- | -- | -- | 1.07 | -- | -- | -- | -107.37 | -- | -- | -- |
| Relay Therapeutics Inc | 8.36m | -297.59m | 1.55bn | 188.00 | -- | 2.53 | -- | 185.02 | -1.75 | -1.75 | 0.0491 | 3.52 | 0.0104 | -- | -- | 32,015.33 | -37.20 | -31.62 | -39.14 | -32.85 | -- | -- | -3,561.43 | -1,130.74 | -- | -- | 0.00 | -- | -60.83 | -- | 1.25 | -- | -24.08 | -- |
| Agios Pharmaceuticals Inc | 44.79m | -401.27m | 1.55bn | 486.00 | -- | 1.20 | -- | 34.54 | -6.96 | -6.96 | 0.7768 | 22.04 | 0.0282 | 0.1959 | 11.00 | 92,162.55 | -25.26 | -10.38 | -26.90 | -11.09 | 87.22 | -- | -895.86 | -768.40 | 13.39 | -- | 0.00 | -- | 36.07 | -- | 291.35 | -- | -32.66 | -- |
| Celldex Therapeutics Inc | 2.60m | -224.53m | 1.58bn | 186.00 | -- | 2.64 | -- | 607.25 | -3.38 | -3.38 | 0.0392 | 9.01 | 0.0035 | -- | 5.52 | 13,978.49 | -30.51 | -27.70 | -32.24 | -29.29 | -- | -- | -8,635.85 | -1,912.91 | -- | -- | 0.00 | -- | 1.99 | 14.46 | -11.62 | -- | 21.29 | -- |
| BioCryst Pharmaceuticals Inc | 599.82m | -8.78m | 1.58bn | 580.00 | -- | -- | -- | 2.64 | -0.0473 | -0.0473 | 2.78 | -1.84 | 1.28 | 2.10 | 7.32 | 1,034,166.00 | -1.87 | -40.01 | -2.96 | -53.68 | 97.39 | 97.34 | -1.46 | -75.69 | 1.83 | 0.9698 | 2.35 | -- | 36.00 | 55.97 | 60.77 | -- | 26.79 | -- |
| Alvotech SA | 573.35m | 69.50m | 1.60bn | 1.01k | 24.46 | -- | 15.19 | 2.78 | 0.2093 | 0.2093 | 1.93 | -0.5671 | 0.434 | 1.53 | 4.30 | 567,111.80 | 5.26 | -- | 6.38 | -- | 55.59 | -- | 12.12 | -201.24 | 0.7376 | 2.57 | 1.16 | -- | 426.84 | 42.86 | 57.98 | -- | 47.91 | -- |
| Oruka Therapeutics Inc | 0.00 | -101.63m | 1.60bn | 28.00 | -- | 3.30 | -- | -- | -2.36 | -2.36 | 0.00 | 10.06 | 0.00 | -- | -- | 0.00 | -22.01 | -32.95 | -22.98 | -34.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1,468.16 | -- | 116.21 | -- |
| Sionna Therapeutics Inc | 0.00 | -70.68m | 1.61bn | 48.00 | -- | 4.99 | -- | -- | -1.61 | -1.61 | 0.00 | 7.23 | 0.00 | -- | -- | 0.00 | -26.35 | -- | -27.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.52 | -- | -- | -- |
| Tyra Biosciences Inc | 0.00 | -111.68m | 1.65bn | 60.00 | -- | 5.89 | -- | -- | -1.88 | -1.88 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -32.73 | -24.74 | -34.14 | -25.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.09 | -- | 101.48 | -- |
| Definium Therapeutics Inc | 0.00 | -168.10m | 1.66bn | 74.00 | -- | 9.94 | -- | -- | -1.97 | -1.97 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -60.39 | -55.68 | -73.40 | -63.31 | -- | -- | -- | -- | -- | -- | 0.2362 | -- | -- | -- | -13.52 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -105.64m | 1.67bn | 60.00 | -- | 6.40 | -- | -- | -11.08 | -11.08 | 0.00 | 9.02 | 0.00 | -- | -- | 0.00 | -77.05 | -49.22 | -84.35 | -54.31 | -- | -- | -- | -4,359.44 | -- | -- | 0.00 | -- | -- | -- | -11.19 | -- | -32.77 | -- |
Data as of Feb 06 2026. Currency figures normalised to Agios Pharmaceuticals Inc's reporting currency: US Dollar USD
54.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Farallon Capital Management LLCas of 30 Sep 2025 | 5.78m | 9.91% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.14m | 8.81% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 3.98m | 6.83% |
| Erste Asset Management GmbHas of 30 Sep 2025 | 2.76m | 4.74% |
| Paradigm BioCapital Advisors LPas of 30 Sep 2025 | 2.67m | 4.59% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 2.41m | 4.13% |
| Commodore Capital LPas of 30 Sep 2025 | 2.34m | 4.01% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 2.26m | 3.88% |
| Erste Asset Management GmbH (Czech Republic)as of 30 Jun 2025 | 2.22m | 3.81% |
| Nomura Investment Management Business Trustas of 30 Sep 2025 | 1.96m | 3.36% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
